UiPath (NYSE:PATH) Price Target Cut to $17.00

UiPath (NYSE:PATH) had its target price reduced by JPMorgan Chase & Co. from $19.00 to $17.00 in a report published on Wednesday morning, Benzinga reports. They currently have an overweight rating on the healthcare company’s stock.

Several other equities research analysts have also issued reports on the stock. Needham & Company LLC reiterated a “hold” rating on shares of UiPath in a research note on Wednesday. BMO Capital Markets boosted their price objective on shares of UiPath from $14.00 to $15.00 and gave the stock a “market perform” rating in a research note on Friday, September 6th. Morgan Stanley restated an “equal weight” rating and set a $15.00 price objective on shares of UiPath in a research note on Friday, September 6th. Royal Bank of Canada restated a “sector perform” rating and set a $16.00 price objective on shares of UiPath in a research note on Friday, September 6th. Finally, TD Cowen lowered their price objective on shares of UiPath from $17.00 to $16.00 and set a “hold” rating on the stock in a research note on Friday, September 6th. Sixteen analysts have rated the stock with a hold rating and two have issued a buy rating to the company’s stock. According to MarketBeat, the stock currently has a consensus rating of “Hold” and an average price target of $17.47.

UiPath Trading Down 1.0 %

Shares of PATH stock opened at $12.35 on Wednesday. UiPath has a 1 year low of $10.37 and a 1 year high of $27.87. The firm’s fifty day moving average price is $12.50 and its two-hundred day moving average price is $14.10. The firm has a market capitalization of $6.79 billion, a P/E ratio of -61.75 and a beta of 0.88.

UiPath (NYSE:PATH) last issued its quarterly earnings results on Thursday, September 5th. The healthcare company reported $0.04 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.03 by $0.01. UiPath had a negative net margin of 8.13% and a negative return on equity of 3.98%. The firm had revenue of $316.00 million for the quarter, compared to analyst estimates of $303.69 million. During the same period in the previous year, the business earned ($0.09) EPS. The company’s revenue was up 10.0% compared to the same quarter last year. As a group, equities research analysts forecast that UiPath will post -0.23 EPS for the current fiscal year.

Insider Buying and Selling

In other UiPath news, CFO Ashim Gupta sold 47,671 shares of the business’s stock in a transaction dated Friday, September 13th. The shares were sold at an average price of $12.07, for a total value of $575,388.97. Following the completion of the sale, the chief financial officer now owns 849,917 shares of the company’s stock, valued at $10,258,498.19. The trade was a 0.00 % decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available at the SEC website. 22.37% of the stock is currently owned by insiders.

Institutional Trading of UiPath

Institutional investors have recently bought and sold shares of the business. Future Financial Wealth Managment LLC bought a new stake in UiPath in the 3rd quarter valued at about $26,000. JTC Employer Solutions Trustee Ltd bought a new stake in UiPath in the 3rd quarter valued at about $26,000. ORG Partners LLC boosted its holdings in UiPath by 875.6% in the 1st quarter. ORG Partners LLC now owns 1,239 shares of the healthcare company’s stock valued at $27,000 after purchasing an additional 1,112 shares during the period. Hantz Financial Services Inc. bought a new stake in shares of UiPath during the 2nd quarter worth approximately $28,000. Finally, Redwood Wealth Management Group LLC bought a new stake in shares of UiPath during the 2nd quarter worth approximately $43,000. Institutional investors own 62.50% of the company’s stock.

UiPath Company Profile

UiPath Inc provides an end-to-end automation platform that offers a range of robotic process automation (RPA) solutions primarily in the United States, Romania, the United Kingdom, the Netherlands, and internationally. The company offers a suite of interrelated software to build, manage, run, engage, measure, and govern automation within the organization.